-
公开(公告)号：EP1268507A1
公开(公告)日：2003-01-02
申请号：EP01916307.0
申请日：2001-03-01
CPC分类号： C12N15/113 , A61K38/00 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , C07H21/00 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , Y02P20/582 , C12N2310/3525
摘要： Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.
摘要翻译： 提供了用于调节E2F转录因子1的表达的反义化合物，组合物和方法。所述组合物包含靶向编码E2F转录因子1的核酸的反义化合物，特别是反义寡核苷酸。使用这些化合物调节E2F转录因子1 表达和用于治疗与E2F转录因子1表达相关的疾病。
-
公开(公告)号：EP0672193A1
公开(公告)日：1995-09-20
申请号：EP93922788.0
申请日：1993-09-29
发明人： HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BENNETT, C., Frank , CHIANG, Ming-Yi , BROWN-DRIVER, Vickie, L. , ECKER, David, J. , VICKERS, Timothy, A. , WYATT, Jacqueline, R. , IMBACH, Jean, Louis Impasse des Lucques
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
-
3.发明授权USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT 失效具有保持G4 KEY序列的寡核苷酸用于生产药物的应用
公开(公告)号：EP0672193B1
公开(公告)日：2002-08-14
申请号：EP93922788.0
申请日：1993-09-29
发明人： HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BENNETT, C., Frank , CHIANG, Ming-Yi , BROWN-DRIVER, Vickie, L. , ECKER, David, J. , VICKERS, Timothy, A. , WYATT, Jacqueline, R. , IMBACH, Jean, Louis Impasse des Lucques
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
-
公开(公告)号：EP0692930A1
公开(公告)日：1996-01-24
申请号：EP94910879.0
申请日：1994-03-07
发明人： DRAPER, Kenneth, G. , CROOKE, Stanley, T. , MIRABELLI, Christopher, K. , ECKER, David, J. , HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BROWN-DRIVER, Vickie, L. , WYATT, Jacqueline, R.
CPC分类号： C12N15/1133 , A61K31/70 , A61K38/00 , C07H21/00 , C07K14/005 , C12N15/1137 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/3125 , C12N2310/315 , C12N2310/321 , C12N2310/33 , C12N2310/346 , C12N2310/3517 , C12N2310/3521 , C12N2710/16622 , C12Q1/701 , C12Y207/07049 , C12Y301/01004
摘要： Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.
-
-
-
搜索结果
4 条记录 (耗时 0.009 秒)
